Intravenous thrombolysis use before interhospital transfer for thrombectomy: a systematic review and meta-analysis.

J NeurolSep 28, 2026 (epub)
Clinical ResearchNeurologyEmergency MedicineOpen access

Zixin Wang, Yun Chen, Jiamin Li et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the impact of intravenous thrombolysis (IVT) before interhospital transfer for endovascular thrombectomy (EVT) in patients with large-vessel occlusion acute ischemic stroke (LVO-AIS). The analysis of 16 observational studies found that pre-transfer IVT significantly improved rates of excellent functional outcomes (OR 1.72) and reduced 90-day mortality (OR 0.69) without increasing hemorrhagic risks.

Key findings

  • Pre-transfer IVT was associated with a higher rate of excellent functional outcome (OR 1.72, 95% CI 1.47-2.01).
  • There was a significant reduction in 90-day mortality with pre-transfer IVT (OR 0.69, 95% CI 0.59-0.81).
  • Interhospital recanalization rates were significantly higher with pre-transfer IVT (OR 7.71, 95% CI 4.08-14.55).
  • No significant differences in the risk of symptomatic intracranial hemorrhage were observed (OR 0.75, 95% CI 0.50-1.11).

Why it matters

The findings suggest that administering IVT before transferring LVO-AIS patients for EVT can enhance functional recovery and reduce mortality, which is crucial in optimizing treatment strategies in acute stroke care.

Source

PubMed · PMID 42803981Free full text on PubMed Central

Published in J Neurol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.